-
-
-
-
-
-
-
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
-
-
-
-
-
-
-
Axsome acquires Avenue's subsidiary for epilepsy drug development
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
-
-
-
-
-
-
-
FDA grants orphan drug status to Mustang Bio's brain cancer treatment
-
-
-
-
-
-
-
Fortress Biotech (FBIO) Closes Sale of Checkpoint Therapeutics
-
-
-
-
-
-
-
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
-
1,154,889 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

